Inactive Instrument

The Valens Company Inc.

VLNS

CA91914P6030

Valens : CEO to Participate in ATB Capital Markets' 9th Annual Institutional Investor Conference

January 11, 2021 at 05:31 pm IST

KELOWNA, BC, Jan. 11, 2021 /CNW/ - The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the "Company" or "The Valens Company"), a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, is pleased to announce that Tyler Robson, CEO of The Valens Company, will participate in the ATB Capital Markets 9th Annual Institutional Investor Conference being held on January 12-14, 2021.

The Valens Company Logo (CNW Group/The Valens Company)

Mr. Robson is scheduled to join David Kideckel, ATB Managing Director and Senior Research Analyst, for a fireside chat titled "Cannabis 2.0... 3.0... and Beyond" on Thursday, January 14, 2021 at 9:00 am ET. Management will also host one-on-one investor meetings throughout the duration of the conference.

About The Valens Company
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company's wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit http://thevalenscompany.com. The Valens Company's investor deck can be found specifically at http://thevalenscompany.com/investors/.

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-valens-company-ceo-to-participate-in-atb-capital-markets-9th-annual-institutional-investor-conference-301204796.html

SOURCE The Valens Company

Latest news about The Valens Company Inc.

The Valens Company Inc.(NasdaqCM:VLNS) dropped from NASDAQ Composite Index	17/23/17	CI
SNDL Inc. completed the acquisition of remaining 91.9% stake in The Valens Company Inc..	17/23/17	CI
Valens Gets Final Court Order Approving Proposed Arrangement With SNDL	04/23/04	MT
The Valens Co Obtains Final Court Order Approving Proposed Arrangement With SNDL	04/23/04	MT
The Valens Company Obtains Final Court Order Approving Proposed Plan of Arrangement With SNDL	04/23/04	MT
The Valens Company Granted Additional 180-Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule	14/22/14	MT
North American Morning Briefing : Investors Wary -2-	14/22/14	DJ
The Valens Co Brief: Granted Additional 180 Calendar Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule	14/22/14	MT
Valens Gets Additional 180-Day Period to Regain Nasdaq Compliance	14/22/14	MT
The Valens Company Brief: Says Shareholders Vote in Favour of the Arrangement with SNDL	30/22/30	MT
The Valens Company Brief: Both Institutional Shareholder Services and Glass Lewis & Co. Recommend Shareholders of Co Vote For Proposed Arrangement With SNDL Inc.	22/22/22	MT
Earnings Flash (VLN) VALENS SEMICONDUCTOR Posts Q3 Revenue $23.1M, vs. Street Est of $22.7M	09/22/09	MT
Earnings Flash (VLN) VALENS SEMICONDUCTOR Posts Q3 EPS $-0.02, vs. Street Est of $-0.08	09/22/09	MT
The Valens Company Inc. Secures Sales Licence for Greater Toronto Area Beverage Facility	03/22/03	CI
The Valens Company Brief: Announcing Mailing and Filing of Circular for Special Meeting of Shareholders To Approve Arrangement With SNDL Inc.	28/22/28	MT
The Valens Company Buy Rating Reiterated at Stifel GMP Following FQ3 Results; Price Target Kept at C$1.20	14/22/14	MT
Sector Update: Consumer Stocks Close Near Thursday Session Highs	14/22/14	MT
Sector Update: Consumer Stocks Moderately Higher Compared with Most Other Thursday Sectors	14/22/14	MT
The Valens Company Up After Reporting Third Quarter Fiscal 2022 Financial Results	13/22/13	MT
The Valens Company Says Q3 Net Revenue Fell 15.4% to $20.3 Million	13/22/13	MT
The Valens Company Brief: Co Has Entered into an Arrangement Agreement to be Acquired by SNDL	13/22/13	MT
The Valens Company Brief: Q3 Net revenue decreased 15.4% to $20.3 million in Q3 2022	13/22/13	MT
The Valens Company Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	13/22/13	CI
The Valens Company Inc. Withdraws All Previously Given Financial Guidance	13/22/13	CI
The Valens Company Inc.(TSX:VLNS) dropped from S&P Global BMI Index	19/22/19	CI

Chart The Valens Company Inc.

Duration

Period

More charts

Company Profile

The Valens Company Inc. is a Canada-based company, which is engaged in the manufacturing of cannabinoid-based products. It operates through two segments: Canada and United States and International. Canada segment includes all business-to-business and business-to-consumer activity within Canada. This includes toll processing and co-packing, product sales, and analytical testing. United States and International segment include all activity related to the Green Roads CBD health and wellness manufacturing facility in Florida, United States. Its products are formulated for the recreational, health and wellness, and medical consumer segments and are offered across all cannabis product categories. It also manufactures, distributes, and sells a range of cannabidiol (CBD) products in the United States through its subsidiary Green Roads, Inc. (Green Roads), and distributes medicinal cannabis products to international markets through its subsidiary Valens Australia Pty Ltd (Valens Australia).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+61.53%	85TCr
NOVO NORDISK A/S	+33.75%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+11.74%	23TCr
NOVARTIS AG	+15.11%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	17TCr

Other Pharmaceuticals